Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
92.87
(
1.65%
)
Bitcoin
73,844.99
(
0.39%
)
News Focus
News Focus
Post# of 257662
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123040
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 167702

Wednesday, 10/09/2013 1:56:45 PM

Wednesday, October 09, 2013 1:56:45 PM

Post# of 257662
PTLA starts phase-1/2 trial of JAK inhibitor for “genetically-defined hematologic cancers”:

http://finance.yahoo.com/news/portola-pharmaceuticals-announces-initiation-phase-120000609.html

This program is very far town on the valuation totem pole, below Betrixaban and PRT4445.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up